GSKpro for UK healthcare professionals
Ordering and delivery
DECTOVA▼
Contact | GSKpro UK
Report a possible side effect | GSKpro
Request a contact
Therapy areas | GSKpro UK
VENTOLIN
FLIXOTIDE
BLENREP▼
Ellipta critical error studies in COPD
XEVUDY ▼ (sotrovimab)
JEMPERLI ▼ (Dostarlimab (FOR NI HCP’s ONLY))
JEMPERLI ▼ (Dostarlimab (FOR GB HCP’s ONLY))
Coming soon | GSKpro
Respiratory
Vaccines
GSKpro Home | SHINGRIX
Immunocompromised | SHINGRIX
Immunocompromised Clinical Data | SHINGRIX
GSKpro Implementation | SHINGRIX
GSKpro Impact of Shingles | SHINGRIX
GSKpro SHINGRIX overview | SHINGRIX
GSKpro Efficacy | SHINGRIX
GSKpro Safety | SHINGRIX
Discontinued products | GSK Pro
Therapy areas | GSKpro UK
Video Testimonials: I've Seen Meningitis
Get in touch with the GSK BLENREP ▼ (belantamab mafodotin) team
Mechanism of action | BLENREP ▼ (belantamab mafodotin)
Efficacy in DREAMM-2 trial | BLENREP ▼ (belantamab mafodotin)
Dosing in DREAMM-2 | BLENREP ▼ (belantamab mafodotin)
Safety data from DREAMM-2 | BLENREP ▼ (belantamab mafodotin)
BLENREP ▼ (belantamab mafodotin) | GSKpro for GB healthcare professionals
Professor Agusti
Webinars & events | GSKpro
Get in touch | OMJJARA▼ (momelotinib) UK
GSKpro Arexvy ▼ | Product Information for Healthcare Professionals
JEMPERLI ▼ (dostarlimab) UK
▼ JEMPERLI (dostarlimab) RUBY Trial
▼ JEMPERLI (dostarlimab) Dosing and Treatment Management
Get in touch| ▼JEMPERLI (dostarlimab) UK
JEMPERLI ▼ (dostarlimab) Resource Library UK
AREXVY▼
OMJJARA▼
Products | GSKpro
ZEJULA
This summer, how can GSK help you deliver the non-seasonal shingles National Immunisation Programme?
Resources | GSKpro
Supply
No results. Why not try:
- Checking the spelling of the search term
- Trying a different search term
- Resetting or revising the filter settings (if you used filters to do this search)
Show more
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.